|Bid||0.00 x 1400|
|Ask||0.00 x 1400|
|Day's range||67.88 - 72.46|
|52-week range||26.49 - 85.00|
|Beta (5Y monthly)||1.20|
|PE ratio (TTM)||13.74|
|Earnings date||27 Apr 2021 - 03 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||89.08|
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Under the guidance of CEO Steve MacMillan, Hologic, Inc. ( NASDAQ:HOLX ) has performed reasonably well recently. This...